Skip to main content

Table 1 Separation of T2D patients participating in CVOTs according to the presence (secondary prevention) or absence (primary prevention) of established CVD

From: Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes

Trial Drug Primary prevention Secondary prevention
EMPA-REG Empagliflozin 56 (0.8%) 6964 (99.2%)
CANVAS Canagliflozin 2819 (27.8%) 7323 (72.2%)
DECLARE Dapagliflozin 10 193 (59.4%) 6967 (40.6%)
VERTIS-CV Ertugliflozin 82 (1%) 8155 (99%)
SCORED Sotagliflozin 5440 (51.4%) 5144 (48.6%)
Total   18 590 (35.0%) 34 553 (65.0%)